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Abstract
There are thought to be many different causes that can lead to the development of
infertility in females. Many of the causes for this condition present themselves
before birth, which can predetermine a woman’s fertility capability before she is
even born. The complex process of germ cell development possesses possibilities
for error and malfunction that can have permanent, lasting effects on a developing
fetus. The process of oocyte development is initiated when primordial germ cells
migrate to the embryotic gonad and begin dividing mitotically. As mitosis
proceeds, the process of cytokinesis does not go to completion, which maintains
the cells in cysts. The fundamental process of cyst breakdown occurs, in
conjunction with apoptosis, in order to separate cysts into individual oocytes
surrounded by a number of granulosa cells, known as primordial follicles. The
success of the process of cyst breakdown is thought to be a valuable determinant
of the overall pool of viable primordial follicles that could be used by a female for
fertilization in the future. This developmental process is well conserved across
mammalian species, such as mice and humans.
Hormones are known to play a role in the process of germ cell development via
various signaling pathways. Abundant research has already been conducted to
investigate the role of estrogen in this developmental process, specifically
exploring the hormone’s ability to inhibit cyst breakdown. Similar research has
demonstrated progesterone’s ability to inhibit cyst breakdown, as well, but much
more is yet to be investigated about this steroid hormone. Although specific
progesterone signaling receptors, such as progesterone receptor membrane
component 1 (PGRMC1) and PGRMC2, and proteins, such as the plasminogen
activator inhibitor 1 RNA-binding protein (PAIRBP1), have been identified, their
regulatory functions and interactions within their prospective signaling pathways
have yet to be well researched. In this study, we investigated where PGRMC1,
PGRMC2 and PAIRBP1 were expressed in the fetal and neonatal mouse ovary
via immunocytochemistry. We also investigated when PGRMC1, PGRMC2 and
PAIRBP1 were most strongly expressed in the mouse ovary across germ cell
development via western blotting.
The results demonstrate that the expression of PGRMC1 and PAIRBP1 localize to
the same cells within the mouse ovary, but exhibit different levels of expression
across fetal and neonatal mouse development. In regards to PGRMC2, the results
reveal a complete lack of expression of this membrane receptor in the mouse
ovary at any time throughout the process of germ cell development. In order to
validate and expand on these results future studies will need to be conducted to
gain more information about the independent and interactive functions of
PGRMC1, PGRMC2 and PAIRBP1 in germ cell development.
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Executive Summary

It may be difficult to believe, but reproductive development in mammals
begins while the developing fetus is still in utero. At this time, a female will go
through a complex process in which all of her oocytes will be produced and
maintained in her ovaries. This is a critical mammalian characteristic for females,
considering that they are not capable of producing any more oocytes beyond this
developmental stage. Once the process of oocyte development is complete, the
pool of oocytes will remain dormant until a female reaches reproductive maturity
and is capable of releasing a viable egg for fertilization. However, the process of
fertilization is not always successful and if a woman experiences difficulty
conceiving a child for an extended period of time she could be considered
infertile. There are various factors that can contribute to or cause infertility, with
one of the main considerations being that a dysfunction in the process of oocyte
development while in utero could have a prolonged effect on a woman’s fertility.
The process of oocyte development, also known as germ cell
development, is very complex in nature, involving a wide variety of mechanisms
and signaling pathways in order to proceed normally. It is known that several
steroid hormones play an integral role in mediating this process, by binding to
specific receptors that will activate corresponding pathways that will carry the
signal until it reaches its destination and the intended response is elicited.
Estrogen is a hormone that has been thoroughly researched and is known to be
involved in the process of oocyte development. However, research has also
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demonstrated that exposure to excess levels of this hormone can cause a glitch in
the process, as well. Excess levels of estrogen in the developing ovary can lead to
a deficit in the final number of viable oocytes that a female fetus can possess for
future reproductive purposes.
Progesterone is another hormone that is known to play a role in the
process of oocyte development, but the information that is available regarding the
mechanisms and pathways through which progesterone is transmitted is
staggeringly less than what is available on estrogen. Some previous research has
shown that exposure to excess levels of progesterone can have a similar effect that
estrogen has on the developing oocytes. Still, considering how much less is
known about progesterone than estrogen, this research focuses on learning more
about the role of progesterone throughout oocyte development, specifically
looking at three components of progesterone signaling pathways. We wanted to
concentrate on the progesterone receptor membrane component 1 (PGRMC1)
receptor, PGRMC2 receptor and the plasminogen activator inhibitor 1 RNAbinding protein (PAIRBP1), which all play a role in the progesterone signaling
pathway, but are in desperate need of further investigation.
Since the process of oocyte development is reasonably similar in mice and
humans, mice were used as the model organism for this research. Male and
female mice were mated each the beginning of each week and female mice were
checked for vaginal plugs each day prior in order to determine the exact date on
which gestation began. Fetal mice at 15.5 days post coitum (dpc) and 17.5 dpc,
also known as days after conception, and neonatal pups at post-natal day (PND) 1,
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PND 3 and PND 5 were dissected in order to obtain their ovaries for various
experiments.
The fetal and neonatal mouse ovaries were used for two main
experimental techniques, one of which was immunocytochemistry, or ovary
staining. This process involved treating the dissected ovaries with a primary
antibody that would bind to either the receptor or protein of interest that is thought
to be expressed in the tissue. The ovaries were then treated with a secondary
antibody, containing a fluorescent tag, which would bind to the primary antibody.
The ovaries were also treated with propidium iodide, which would stain the nuclei
of all of the cells in the tissue. Once the staining procedure was complete, the
ovaries were transferred to a slide and were viewed using the confocal
microscope. A confocal microscope is a type of microscope that uses lasers that
are specific to the wavelength at which the tag on a secondary antibody fluoresces
to infiltrate material on a slide. Since the primary-secondary antibody complex is
bound to the receptor or protein of interest, it is possible to view the expression of
the given molecule within the mouse ovary using the confocal microscope and to
take images in order to compare expression and localization patterns across
different stages of oocyte development. Another experimental technique used for
this research was western blotting, which serves to identify specific proteins
within a sample. Dissected ovaries were homogenized in solution, where they
were called ovary extracts. The extracts from different fetal and neonatal ages
were loaded into wells on a gel in chronological order. The molecular components
of the extracts were then separated by molecular size as they were pushed down
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the gel by an electric current; a process called gel electrophoresis. The results
from the gel were then transferred to a membrane, which was incubated with a
primary and secondary antibody that bind in the same manner as discussed with
immunocytochemistry. The primary-secondary antibody complex allowed the
receptor/protein of interest to be detected as bands on the membrane. Whereas
any insignificant molecules found in the extracts were suppressed using a specific
solution that functions to block irrelevant bands.
The results obtained from the immunocytochemistry and western blot
experiments were relatively variable in nature. The images coinciding with the
immunocytochemistry showed that the PGRMC1 receptor and the PAIRBP1
protein were detected in the surface cells of the fetal and neonatal mouse ovary
from 15.5 dpc to PND 5, but not within the oocytes themselves. The
immunocytochemistry images also showed no detection of PGRMC2 anywhere
within the ovary during that same timeframe. The results from the western blots
showed that PGRMC1 was expressed at consistent levels in the mouse ovary from
15.5 dpc to PND 5, but PAIRBP1 showed increased expression as oocyte
development proceeds. Similar to the immunocytochemistry results obtained for
PGRMC2, there didn’t appear to be any expression of PGRMC2 from 15.5 dpc to
PND 5.
Given the inconclusive results, future studies will need to be conducted in
order to learn more about PGRMC1, PGRMC2 and PAIRBP1 and their dynamic
function in the process of oocyte development. The experiments completed here
will need to be repeated in order to obtain more conclusive data. Other types of
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experiments, such as organ cultures, could be extremely beneficial in
investigating the function of these progesterone signaling components and their
long-term effect on oocyte development. Organ culture experiments would
involve growing ovaries in a completely sterile environment for several days in a
special solution that will block the function of the corresponding receptor/protein
as the ovaries develop. Once the organ culture is complete, the ovaries can be
stained using the immunocytochemistry protocol in order to determine how the
function-blocking mechanism affects the overall number of individual oocytes
that are present at the end of oocyte development.
The field of research that is dedicated to exploring the role of progesterone
in oocyte development and the hormone’s corresponding signaling pathways is
expanding and will hopefully continue to grow in the coming years. Recent
research has focused more on how progesterone receptors, such as PGRMC1 and
PGRMC2, play a role in cancer, which is of crucial importance. However,
continued research revolving around progesterone signaling receptors and
proteins could assist in a better understanding of the complex process of oocyte
development and the potential infertility conditions that could arise if a
malfunction occurs.
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Introduction

The act of reproducing is an innate human function that is necessary for
the survival of our species. The process of reproduction is quite diverse across
species, but the overall goal is unanimous; to procreate in order to maintain our
existence. In terms of human reproduction, the process is extremely complex and
has evolved to signify more than strictly procreation. There are so many minute
details and functions that must simultaneously work in unison in order to
successfully conceive a child that it is no surprise that infertility is a prominent
issue that people are continuing to struggle with.
Roughly 12% of women in the United States, who are at reproductive age,
face difficulties with fertility (Chandra et al., 2006). In retrospect, this is a
significant proportion of women that are experiencing fertility issues, often times
not knowing exactly what the cause is or how to go about fixing it. A major
concern to consider is the fact that women produce their complete supply of
viable eggs long before they even consider reproducing. With no ability to
produce any more eggs after that crucial point in development, it is impossible to
realize the reproductive outcome until it is too late (Skinner, 2005). During this
process of oocyte development, which is complete and irreversible upon birth, a
woman loses a significant percentage of potential oocytes. Even though this rapid
decrease in oocyte numbers is observable, it is far from being completely
understood or explained. If we had a clearer and more concise understanding of
the various processes involved in oocyte development, specifically focusing on

sporadic oocyte loss, then we could potentially gain a better understanding of
possible infertility triggers and how to better aid individuals being affected by
difficulties with infertility.
Although, ideally, we would prefer to learn more about this complex
process in humans, it is more realistic and feasible to study the process of oocyte
development in a model organism that is most similar to humans in terms of
reproductive qualities. In the Pepling Lab we use the species Mus musculus as a
model organism for research purposes. Being one of the most closely related
model organisms to humans, mice share a number of commonalities with humans
in this aspect of development, which makes the results obtained from research
somewhat transferable across species. The mouse genome is entirely sequenced,
which makes it a reliable organism to use for research purposes since a great deal
of background information has already been collected. This fully sequenced
genome is also relatively easy to manipulate in order to create a variety of
genetically modified, or transgenic, strains of mice to be used for research. The
ability to quickly and easily produce transgenic mice is a predominant quality that
makes the species so marketable for biological research.
In terms of laboratory use, mice are a relatively easy model organism to
contain in a laboratory setting. They are small in size and easily maintainable.
They are not a difficult species to breed and their embryonic development is
relatively short, lasting 19.5 days on average, with a relatively larger number of
pups being produced. The short gestation period, coupled with the larger number
of pups being born in relation to other mammals, provides opportunities to
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acquire a large amount of data across a short period of time. This turnover rate
would not be possible using other mammalian model organisms that possess
relatively the same similarity to humans, but require a longer gestation period and
give birth to a smaller number of offspring.
As in human females, female mice begin the reproductive process long
before birth. Initially, precursor cells, known as primordial germ cells migrate to
the developing gonad of the fetus at approximately 10.5 days after conception,
also known as days post coitum (dpc) (Pepling, 2006). Upon arrival at the gonad,
the primordial germ cells begin to divide via mitosis, forming clusters

Figure 1: A timeline of mouse germ cell development ranging from 11 dpc to
PND 6. Significant developmental stages are labeled, with the green structures
representing germ cells and the red structures representing somatic granulosa cells
(adapted from Pepling, 2006).
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known as germ cell cysts (Pepling and Spradling, 1998). At this stage, the
primordial germ cells divide mitotically, where cytokinesis does not go to
completion and the cells of the cyst remain connected by intercellular bridges
(Pepling et al., 1999). At this point the cells are known as oogonia. Once the
process of mitosis is complete, the oogonia begin the process of meiosis at
roughly 13.5 dpc, as shown in Figure 1, and become oocytes. However, the
meiotic process is then arrested at the diplotene stage of meiosis I. It was thought
that the process of meiosis and the consecutive meiotic arrest occur at precisely
the same time, across all oocytes, but it has been determined that the meiotic
process often does not occur collectively for all oocytes (Pepling, 2006). The
oocytes remain in cysts, surrounded by somatic cells, for several consecutive days
of development. As shown in Figure 1, at roughly 18 dpc, cyst breakdown is
triggered and the compacted germ cell cysts begin to separate. This process of
cyst breakdown signals the maturation of the germ cells into individual oocytes.
Following the days after birth, also known as post-natal days (PND), cyst
breakdown progresses. By PND 5, the majority of the germ cells have matured
and formed individual primordial follicles, containing a single oocyte surrounded
by a layer of granulosa cells, as shown in Figure 1 (Pepling and Spradling, 2001).
The timing of cyst breakdown coincides with another fundamental process
that occurs during oocyte development, germ cell death. As shown in Figure 1,
only slightly after the beginning of cyst breakdown is randomized germ cell
death, known as apoptosis, initiated. In an older scientific model it is thought that
the ongoing process of cyst breakdown is facilitated by continued apoptosis of
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A

Figure 2: Images depicting the difference between a normal follicle (A) versus a
multiple oocyte follicle (B) in the adult ovary. The green staining signifies STAT
3 antibody staining the cytoplasm of the oocytes and the red staining signifies
propidium iodide staining the nuclei of the oocytes, as well as the nuclei of the
granulosa cells (Pepling, 2006).

cells within the cysts, demonstrating that cell death is essential in order for this
process to occur and, in turn, the formation of primordial follicles (Pepling and
Spradling, 2001). However, sometimes cyst breakdown does not go to completion
and an irregular follicle, known as a multiple oocyte follicle (MOF), forms.
Multiple oocyte follicles consist of several oocytes enclosed within a single
follicle, surrounded by a layer of granulosa cells, as depicted in Figure 2. These
MOFs are thought to contain inviable eggs for future reproduction and, therefore,
could potentially contribute to causes of infertility.

A

B

C

Figure 3: Structures of the hormones discussed, including estrogen (A), estradiol
(B) and progesterone (C).
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The process of cyst breakdown, coupled with apoptosis, is a critical stage
in oocyte development that we are consistently attempting to gain a better
understanding of. Prior research has demonstrated that steroid hormones such as
estrogen, specifically in the form of estradiol, as shown in Figure 3, possess the
ability to inhibit cyst breakdown. This inhibition of cyst breakdown leads to a
decreased number of functional oocyte follicles in the ovary, which could, in turn,
lead to an increased chance for infertility (Chen et al., 2007; Jefferson et al.,
2006). Additional hormones, such as progesterone, have been shown to block cyst
breakdown in the neonatal mouse ovary when expressed at high levels, as well.
Even though the function of estrogen, in the form of estradiol, on cyst breakdown
in female mice has received vast attention, progesterone is also a hormone that
produces roughly the same effects (Chen et al., 2007). Estrogen and progesterone
individually have the ability to alter the process of cyst breakdown, but these
hormones are also known to additively block cyst breakdown when their effects
are combined.
Progesterone, as shown in Figure 3, is a naturally occurring hormone that
plays a crucial role in a number of different functions throughout the body.
Progesterone is known to be involved in hypothalamus and pituitary activity, as
well as mammary gland and uterine development. The most significant
application of progesterone for research in the Pepling Lab focuses on the role of
progesterone in intra-ovarian activity, specifically follicular development.
Progesterone continues to play a consistent role in future female reproductive
processes, ranging from menstruation to menopause. This demonstrates how
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crucial of a contributor progesterone is throughout a woman’s lifetime, starting
before birth. In order for progesterone to serve these various functions, a number
of different signaling pathways must be utilized in order to distinguish between
particular functions in which progesterone is necessary at different points in time.

Figure 4: Diagram depicting the potential steps involved in the inhibition of cyst
breakdown upon the binding of progesterone to either a nuclear receptor or a
membrane receptor. P represents the progesterone signal and the biological
function produced in this particular case would be the inhibition of cyst
breakdown (Dzadyk, unpublished).

The signaling pathways of steroid hormones vary, but, as with any
signaling pathway, the receptors play a crucial role in the progression of the
signal, whether it is an estrogen or progesterone signaling pathway. As shown in
Figure 4, progesterone signaling can occur in a variety of ways through either
nuclear or membrane receptors that could potentially signal to inhibit cyst
breakdown in the mouse ovary (Peluso, 2006). Nuclear receptors such as
progesterone receptor-A (PR-A) and progesterone receptor-B (PR-B) originate
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from the same gene and are translocated to the nucleus upon binding progesterone
in the cytoplasm (Pepling, 2012). The translocated receptor/hormone complex
activates regions of target genes that will elicit the intended progesterone response
via transcriptional and translational mechanisms (Leonhardt et al., 2003). This
signaling pathway is thought to take relatively longer than alternative
progesterone signaling pathways, seeing as transcriptional and translational
mechanisms proceed over a longer period of time.
Another known progesterone signaling pathway involves the use of
cellular membrane receptors, known as progesterone receptor membrane
components (PGRMCs). Known cellular membrane receptors that play a role in
progesterone signaling are PGRMC1 and PGRMC2. Progesterone binds to these
receptors, a secondary messenger is activated and a signaling cascade proceeds
until the desired biological function is produced. Not nearly as much is known
about these cellular membrane receptors as is known about the nuclear receptors,
which is why they are of particular interest in this research. However, previous
studies have demonstrated that the term cellular membrane receptor is somewhat
of a misnomer, because these receptors are not strictly limited to the cellular
membrane. Even though they were first discovered in the cellular membrane, they
have since been found to be expressed in the nucleus, as well as a number of other
intercellular membranes, such as the membranes of endoplasmic reticulum,
depending on the type of cell they are localizing in (Wendler and Wehling, 2013).
These observations further intrigue researchers to learn more about PGRMC1 and
PGRMC2, their origins and applications in mouse oocyte development.
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Slightly more information is known about PGRMC1 and more current
research is being conducted in order to learn more about the function of this
receptor. Although PGRMC1 has been shown to be involved in a number of
functions outside of the ovary, it does play a significant role in later stages of
oocyte development, leaving the question of whether or not it affects earlier
developmental processes, such as cyst breakdown and apoptosis, as well.
PGRMC1 acts to mediate progesterone activity and these receptors are a prime
candidate due to the fact that they possess such a strong binding affinity for
progesterone (Peluso, 2013). PGRMC1 serves as a mediator for the anti-apoptotic
function that progesterone expression induces, either enhancing the effect and
reducing the number of germ cells lost or reducing the effect if the receptor is
inhibited, leading to a spike in apoptotic activity (Peluso et al., 2008). This
function of PGRMC1 is important since the coupled processes of apoptosis and
cyst breakdown are both influenced by progesterone, with progesterone having an
anti-apoptotic effect on the process of germ cell death that coincides with
inhibited cyst breakdown. Learning more about the use of the PGRMC1 signaling
pathway for the anti-apoptotic effect of progesterone will only help us gain more
information regarding progesterone’s synchronous effect on cyst breakdown.
Unlike other estrogen and progesterone receptors, research studies on
PGRMC1 have found the receptor to localize to a number of different areas,
including the nucleus, the cytoplasm and other intracellular membranes in the
ovary (Lösel et al., 2008). This localization pattern is conserved within mice and
humans, and, specifically in granulosa cells within the ovary, PGRMC1 is
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expressed in the plasma membrane, the cytoplasm and sometime the nucleus
(Peluso, 2006). Granulosa cells act as protective, nursing cells surrounding the
individual oocytes, and since progesterone manipulates granulosa cell function via
the PGRMC1 receptor, it allows for the consequential manipulation of oocyte
development. Alterations in these PGRMC1-progesterone interactions have been
shown to have effects on future female reproductive processes, and, in turn,
fertility capabilities.
Even less information is known about PGRMC2, with minimal recent
research having been conducted in order to gain more knowledge about the
receptor and its functions. The majority of current information available on this
receptor has been obtained from studies conducted using rats as the model
organism, and the researched presence of PGRMC2 in humans does not explicate
that the receptor is strictly present in the female ovary (Cahill, 2007; Chen et al.,
2010). Limited information that is known states that PGRMC2 is quite
homologous to PGRMC1 (Albrecht et al., 2012). Some research has been
conducted studying the effects of PGRMC2 on ovarian cancer cells, and its
potential to act as a tumor suppressor (Albrecht et al., 2012). This potential
PGRMC2 function differs drastically from PGRMC1 seeing as PGRMC1 is
thought to be a tumor promoter when studying cancer cells. Even though some
research has investigated the role of PGRMC2 in cancer cells, little information is
known regarding the role of PGRMC2 in oocyte development. Previous studies in
the Pepling Lab, using immunocytochemistry, have demonstrated that the
progesterone receptor, PGRMC2, is present in the fetal mouse ovary at 15.5 dpc
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(Dzyadyk and Pepling, unpublished). However, further research looking into the
expression of PGRMC2 throughout the entirety of mouse oocyte development
will be discussed later on in the paper.
There are several other proteins that are thought to interact with either
PGRMC1 or PGRMC2, or both receptors, and researchers are attempting to gain
more information about these proteins in order to learn more about the receptors
that they work together with. The plasminogen activator inhibitor 1 RNA-binding
protein (PAIRBP1) is thought to interact with PGRMC1 in the PGRMC1progesterone signaling pathway. Since PAIRBP1 does not appear to possess any
type of transmembrane domain that could allow the protein to function as a
receptor in a signal transduction pathway, PAIRBP1 binds to and uses PGRMC1
as a means to affect the progesterone signaling pathway (Peluso, 2006).
Even though progesterone’s effect on cyst breakdown in mouse germ cell
development has been discussed, progesterone is also known to have an inhibitory
effect on the process of apoptosis. Although the signal mechanism of PAIRBP1 is
unknown, the interaction between PAIRBP1 and PGRMC1 is thought to be
necessary in order for progesterone to successfully inhibit apoptosis (Peluso et al.,
2013). This anti-apoptotic function has a prominent effect on granulosa cells and
spontaneously immortalized granulosa cells, specifically in the rat. The fact that
PGRMC1 is known to be expressed in numerous areas throughout the granulosa
cell, whereas PAIRBP1 has been found to be expressed only in the plasma
membrane and cytoplasm of these cells, could be signifying the limitations of
PAIRBP1 activity as a component of the progesterone-PGRMC1 signal
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transduction pathway that does not affect the cell at a nuclear level. It is believed
that there is a particular amino acid sequence in PGRMC1 that is responsible for
its binding with PAIRBP1, and studies have been conducted using this amino acid
sequence in order to understand its implications on the PGRMC1-PAIRBP
interaction and how manipulations of this sequence can affect biological
processes on a larger scale (Peluso et al., 2013).
Again, not nearly as much information is known about the potential
interaction of the PAIRBP1 protein with PGRMC2. However, since PGRMC2 is
a member of the PGRMC family and shares a number of similarities with
PGRMC1, it is thought that a similar anti-apoptotic effect is dependent upon an
interaction between PAIRBP1 and PGRMC2. The crucial amino acid sequence
found in PGRMC1 is known to be roughly 80% identical in PGRMC2,
demonstrating that the effects of this sequence could be transferable across either
member of the PGRMC family (Peluso et al., 2013).
The goal of this research is to gain a more in depth understanding of
PGRMC1 and PGRMC2 as individual contributors, as well as the PAIRBP1
protein, to the intricate processes involved in oocyte development within the
mouse ovary. If we can acquire more detailed knowledge regarding the
timeframes in which these membrane receptors and corresponding protein are
expressed throughout oocyte development and the level of expression at each
crucial stage, then maybe we could gain a more clear and concise understanding
of each stage of oocyte development, specifically cyst breakdown and apoptosis,
which could have such direct effects on future fertility concerns.
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Materials and Methods

Animals

Research in the Pepling Lab was conducted using the species, Mus
musculus, as the model organism. The specific transgenic strain of mice that I
used for my research was the inbred strain, C57BL/6J (B6). Mice were originally
supplied from companies, such as Jackson Labs, but breeding also took place
within the laboratory animal resource facility located on campus at Syracuse
University. All of the mice used for experiments were maintained and cared for in
the laboratory animal resource facility, as well, with collaborative efforts between
members of the Pepling Lab and the laboratory animal facility staff.
Matings between male and female B6 mice were set up every Monday
afternoon at approximately 2PM, caging 2 females with 1 male per cage. Females
were then checked for a vaginal plug each morning before 10AM for the
remainder of the week as a sign of conception. Females that appeared to have a
vaginal plug were isolated and their plug date was recorded in order to keep track
of expected birth dates for litters of mice. On the final day of the mating week,
regardless of whether or not a female mouse had conceived, the females were
isolated. Pregnant females would then give birth approximately 19.5 days after
conception, also known as days post coitum (dpc). The day of birth was known as
post-natal day 1 (PND 1) and every day after the pups’ birth is referenced in terms
of post-natal days. Occasionally, litters would not necessarily be born on the
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expected due date, but the age of litters was always determined strictly by plug
date, not by birth date, when considering ages of litters for research purposes.

Dissection

For my particular project, I obtained ovaries from B6 litters ranging from
15.5 dpc through PND 5. This required performing fetal dissections and post-natal
dissections. Fetal dissections required euthanizing the pregnant female by CO2
asphyxiation using a Euthenex machine in order to dissect the fetal pups. Fetal
pups were removed from the amniotic sac and separated from the placenta in
order to dissect them individually. Pups taken at post-natal day ages were simply
removed from the mother’s cage for dissection and were sacrificed by
decapitation. A dissecting microscope was used in order to magnify the animals
that were being dissected and dissections took place in phosphate buffered saline
(PBS) solution, which served as a solution similar to where the ovaries were
naturally maintained. Once dissection of the ovaries was complete, ovaries were
transferred to a solution known as fix, which consists of 200 µL of 16%
formaldehyde and 400 µL of 1x PBS. The ovaries were placed in fix in order to
preserve the tissue at the stage at which it was dissected and to prevent the ovaries
from deteriorating. Ovaries were then incubated in this solution overnight at 4˚C
on a nutator in a tube labeled with the age at which the ovaries were dissected, the
dissection date and the number of ovaries collected. The stored ovaries could then
be used for future experiments, such as whole mount antibody staining.
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Whole Mount Antibody Staining

After being incubated overnight in the solution of fix, a detailed protocol
was followed to perform an antibody staining procedure using indirect
immunofluorescence. Typically, I focused on collecting data from antibody
stainings performed at 15.5 dpc, since the various antibodies that I use are thought
to be highly expressed at that stage in mouse oocyte development. Therefore, the
specific protocol that I followed was designed specifically for antibody staining of
fetal mouse ovaries. Following incubation in fix, ovaries were quickly washed
two times in 1 mL of PT, which is a solution consisting of 1x PBS and 0.1% of
Triton X-100. Then, they were incubated in 1mL of PT for approximately 30
minutes at room temperature on a nutator. Next, the ovaries were incubated in 1
mL of PT + 5% BSA. The incubation time in PT + 5% BSA could be modified in
several different ways. The ovaries could either be incubated in the solution for 1
hour at room temperature on a nutator or the ovaries could be incubated in the
solution overnight on a nutator at 4˚C. Either method yielded identical results and
did not affect the end product.
After incubation in the PT + 5% BSA solution, the ovaries were incubated
with the primary antibody being used in the staining procedure. Different
antibodies have certain dilutions at which they will optimally label the tissue in
immunofluorescence procedures, so I used several different primary antibody
dilutions throughout the various antibody stainings that I performed. As
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Table 1: Primary antibodies used in whole mount antibody staining
procedure
Primary
antibody

Company

Lot Number

PGRMC1

Santa Cruz
Biotechnology

C1510

PGRMC1

Sigma Aldrich

PGRMC2

Santa Cruz
Biotechnology

PGRMC2

Sigma Aldrich

PAIRBP1

Abcam

STAT 3

Santa Cruz
Biotechnology

Antibody
function

labels
PGRMC1
receptor
C41005
labels
PGRMC1
receptor
L0312
labels
PGRMC2
receptor
R38704
labels
PGRMC2
receptor
GR151078-1 labels
PAIRBP1
protein
I0613
oocyte
marker

Dilution
amount
used in 500
µL of
PT+5%
BSA
5 µL

5 µL

5 µL

5 µL

5 µL

1 µL

shown in Table 1, when staining for the expression of STAT 3, a dilution factor of
1:500 was used; whereas staining for the expression of PGRMC1, PGRMC2 or
PAIRBP1 required a larger concentration of antibody with a dilution factor of
1:100 in order to adequately express the proteins of interest. However, the nature
of the solution in which the primary antibody was diluted, and the exact volume
of that solution used, was consistently 500 µL of PT + 5% BSA. After adding the
PT + 5% BSA and the appropriate primary antibody, the ovaries were incubated
overnight on a nutator at 4˚C. At this time, the solution containing the secondary
antibody was made in order to allow the secondary antibody to appropriately pre-
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absorb. A very small pinch of embryo powder, 500 µL of PT + 5% BSA and 2.5
µL of the corresponding secondary antibody are all added together in a tube and
incubated overnight on a nutator at 4˚C alongside the ovaries being incubated in
the primary antibody. The different secondary antibodies used depending on the
species in which the primary antibody originated are listed in Table 2. The
secondary antibody solution was maintained in foil the entire time, since it is
fluorescent and light sensitive, which are characteristics that make it possible to
visualize the stained ovaries at the end of the procedure.

Table 2: Secondary antibodies used in whole mount antibody staining
procedure
Secondary
antibody

Company

Wavelength
(nm)

Antibody
function

donkey antigoat

Molecular
Probes

488 nm

donkey antimouse

Molecular
Probes

488 nm

donkey antirabbit

Molecular
Probes

488 nm

goat antimouse

Molecular
Probes

488 nm

goat anti-rabbit Molecular
Probes

488 nm

rabbit anti-goat Molecular
Probes

488 nm

indirectly
labels
PGRMC2
indirectly
labels
PAIRBP1
indirectly
labels
PGRMC1and
PGRMC2
indirectly
labels
PAIRBP1
Indirectly
labels
PGRMC1 and
Stat 3
indirectly
labels
PGRMC2

Dilution
used in
500µL
PT+5%
BSA (µL)
2.5 µL

2.5 µL

2.5 µL

2.5 µL

2.5 µL

2.5 µL
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The following day, the ovaries were washed in 1 mL of PT + 1% BSA for
no less than 30 minutes on a nutator at room temperature. Then, the ovaries were
incubated in RNase A solution, containing 10 µL of 10 mg/mL RNase A and 1
mL of PT + 1% BSA, for exactly 30 minutes on a nutator at room temperature.
Next, the ovaries were incubated in a solution containing 10 µL of 0.5 mg/mL
propidium iodide and 1 mL of PT + 1% BSA for exactly 20 minutes on a nutator
at room temperature, in complete darkness in order to preserve the effect of the
propidium iodide. From this point on, all the steps in the staining process were
completed in foil-wrapped tubes in order to preserve the fluorescent staining
reagents. After incubation in propidium iodide, the ovaries were washed in 1 mL
of PT + 1% BSA for approximately 30 minutes on a nutator at room temperature.
The ovaries were then incubated in a solution containing 2.5 µL of the preabsorbed secondary antibody solution with 500 µL of PT + 5% BSA, as shown in
Table 2, for either 2-4 hours on a nutator at room temperature or overnight on a
nutator at 4˚C.
On the final day, the ovaries were washed three separate times in 1 mL of
PT + 1% BSA, for 30 minutes each time, on a nutator at room temperature. The
ovaries were then washed quickly in 1 mL of 1x PBS before mounting the ovaries
on a new slide. In order to transfer the ovaries to the slide, roughly 700 µL of 1x
PBS was removed from the tube containing the ovaries after the wash was
complete. A new pipette tip was then cut at an angle to create a larger opening in
which the ovaries would freely be able to be pipetted out on the tube, into the tip
and back onto the slide. Once the ovaries were transferred to the slide and any
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excess 1x PBS was removed from the slide, 2 drops of VectaShield were added to
the slide. A coverslip was carefully placed on the top of the slide and the ovaries
sat in the VectaShield in the dark for approximately 15 minutes, because the
VectaShield served to further preserve the fluorescent character of both the
propidium iodide and the secondary antibody for visualization later on. Nail
polish was then spread around the exterior of the coverslip in order to ensure that
the coverslip was secure and the slide was labeled with sex of gonads, the age at
which the gonads were dissected, the primary and secondary antibodies used for
the staining, the current date and my personal initials. After the nail polish had
completely dried, the completed slide was placed in a folder to prevent exposure
to light and the folder was stored in the freezer at -20˚C.

Confocal Microscopy

Confocal microscopy is an effective method used to visualize the staining
patterns on a specimen. The microscope uses point illumination to pinpoint a
discrete region of the specimen in which the fluorescent reagent that the specimen
was stained with can be made visible. Ovaries that were stained using the whole
mount antibody staining protocol were visualized using the Zeiss LSM 710
confocal microscope located in the imaging room at the Life Sciences Complex at
Syracuse University. When observing the slides under the microscope, the ovaries
were first looked at using a 10x objective lens, in order to locate and focus on
individual ovaries on the slides. Once an ovary was clearly visible under the 10x
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lens, a drop of oil was added and the magnification was increased to a 63x
objective in order to observe various stages of oocyte development occurring
within the individual ovaries. The confocal microscope was used to analyze the
appropriately labeled proteins that coincided with the antibodies that were used to
stain for their expression during the antibody staining procedure. In this case, in
order to visualize the appropriate fluorescent wavelength, the confocal reflector
used was always alexa-fluoro-488, which would allow the fluorescing secondary
antibody reagent to be made visible under the confocal microscope. Images of the
stained ovaries would be taken on a computer linked to the Zeiss confocal
microscope, using Zen 2010 software, and could then be transferred to a disc for
future reference outside of the imaging room.

Western Blotting

Western blotting is a technique that can be used to test for the presence of
certain proteins at various stages in development. Western blot analysis also
provides subsequent information about the magnitude of protein expression across
developmental stages. In order to determine protein expression throughout oocyte
development, I dissected ovaries at several days of fetal and neonatal
development, specifically 15.5, 17.5 dpc and PND 1, 3 and 5. The dissection
protocol was slightly altered when preparing ovaries for western blotting. Ovaries
were still dissected in 1x PBS, but were then transferred to an eppendorf tube
containing approximately 500 µL of ice-cold 1x PBS. After all of the ovaries
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were dissected and transferred to the tube, the 1x PBS was removed and a
proportionate supply of 1x Sample Buffer plus protease inhibitors was added. 1x
Sample Buffer consists of 500 µL of 2x Sample Buffer, 100 µL of 10x protease
inhibitors and 400 µL of distilled water. For each ovary dissected, 10 µL of 1x
Sample Buffer was added, being sure that only 50 µL of 1x Sample Buffer was
added at a time. Once the first 50 µL of Buffer was added, the ovaries were
homogenized using a pestle and then any additional required Buffer was added to
finish the process. From the moment the ovaries were dissected until the moment
that they were homogenized, it was critical that the ovaries were kept on ice. Once
homogenization was complete, the tube containing the ovary extracts was labeled
with the age of the ovaries, the date of the dissections, the number of ovaries
homogenized and my personal initials. The homogenized ovary extracts were then
stored in the freezer at -20˚C, until they were needed to run a western blot.
Once enough ovary extracts were collected from a variety of fetal and
neonatal ages, the electrophoresis step of the western blot was initiated. In order
to prepare the samples, 20 µL of each extract and 2 µL of 2-mercaptoethanol were
added to an eppendorf tube. The samples were then boiled for 3 minutes and
centrifuged for 1 minute at 6000 rpm, being returned to ice after each step. The
gel apparatus was assembled, the BioRad Mini Protein Gel was inserted into the
gel holder and the appropriate amount of 1x Running Buffer, consisting of 100
mL of 10x SDS Glycine Running Buffer diluted in 900 mL of milli-Q water, was
added. The wells of the gel were cleaned out to avoid bubbling, and then the
samples were loaded into the individual wells. 10 µL of Precision Plus Standard

28

Protein marker were loaded into the first well to serve as a reference ladder.
Positive control lysates were also used as a means of regulating the efficiency of
the protocol being used and to ensure that the antibodies being used were
functioning properly. A Hep G2 cell lysate was used as a positive control for the
PGRMC1 antibody used and a HeLa whole cell lysate was used as a positive
control for the PGRMC2 and the PAIRBP1 antibodies used. 20 µL of each
positive control lysate were loaded into the appropriate wells on the gel. 20 µL of
the boiled and spun ovary samples were then loaded into the wells in order of
increasing age. The gel was then run at approximately 100 volts for 1 hour.
Once electrophoresis was complete, the resulting bands present on the gel
were transferred to a polyvinylidene fluoride transfer membrane for manipulation
with the desired antibodies. Before the transfer procedure occurs, the transfer
membrane was soaked in methanol for 1 minute then milli-Q water for 5 minutes.
The membrane, BioRad gel, 2 pieces of filter paper and 2 filter pads were then
individually soaked in transfer buffer, consisting of 3.0 grams of Tris base, 14.4
grams of glycine and 200 mL of methanol diluted in milli-Q water to a total
volume of 1 liter, for 5 minutes. After being soaked in transfer buffer, a transfer
sandwich was assembled within a transfer cassette, laying one fiber pad, one piece
of filter paper, the gel, the transfer membrane, the second piece of filter paper and
the second filter pad down on the cassette. The closed cassette was then placed in
the transfer apparatus, an ice-cube was added, a small stir bar was placed in the
bottom and the apparatus was filled with transfer buffer. The entire apparatus was
relocated to the 4˚C refrigerator and the transfer took place at 4˚C at 100 volts for
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1 hour. Once the transfer was complete, the membrane was placed in blocking
buffer on a shaker at room temperature for 30 minutes to block any future nonspecific binding of proteins once the detection antibodies were added. After 30
minutes, the blocking buffer was changed and the membrane was incubated in
fresh blocking buffer overnight on the nutator at 4˚C. The blocking buffer used
depended upon the particular detection antibody. When working with a PGRMC1
antibody, a PGRMC2 antibody made in rabbit, or a PAIRBP1 antibody, standard
blocking buffer was used throughout the protocol, which consisted of 100 mL of
10x PBS, 50 g of non-fat dry milk and 0.5 mL Tween 20 diluted in milli-Q water
to a total volume of 1 liter. When working with a PGRMC2 antibody made in
goat, the ingredients of the blocking buffer had to be altered due to the origin of
the antibody. The PGRMC2 antibody used was produced in goat and the milk
used in standard blocking buffer is known to cross-react with antibodies made in
goat, leading to non-specific protein binding. The 5% non-fat dry milk in blocking
buffer was substituted with 50 µL of goat serum (Molecular Probes, Lot #
1114869A) in order to avoid error.
The following day, a primary antibody and its corresponding secondary
antibody were applied to the membrane in order to test for the presence of a
protein of interest. The membrane was first incubated in a solution of the primary
antibody diluted in blocking buffer. The antibody dilution is typically 1:1000, but
varies depending on the particular antibody. As shown in Table 3, the antibodies
used were often diluted much less than normal. The membrane incubation in
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Table 3: Primary antibodies / lysates used for western blotting
Primary
antibody/lysate

Company

Lot
Number

GAPDH

E0912

HeLa whole
cell lysate

Santa Cruz
Biotechnology
Santa Cruz
Biotechnology

Hep G2 cell
lysate

Santa Cruz
Biotechnology

PAIRBP1

Abcam

PGRMC1

Sigma Aldrich

PGRMC2

Santa Cruz

PGRMC2

Sigma Aldrich

Antibody/lysate
function

loading control
antibody
I0612
positive control
lysate for several
antibodies
E1012
positive control
lysate for an
antibody
GR151078- detect expression
1
of PAIRBP1
protein
C41005
detect expression
of PGRMC1
receptor
L0312
detect expression
of PGRMC2
receptor
R38704
detect expression
of PGRMC2
receptor

Dilution in
blocking
buffer
(BB)
1:5000 (1
µL:5mL)
N/A

N/A

1:100 (30
µL: 3 mL
1:500 (6
µL: 3 mL)
1:1000 (3
µL: 3 mL)
1:100 (30
µL: 3 mL)

primary antibody solution varied in time and temperature depending on the nature
of the primary antibody. When the membrane was incubated using PGRMC1 as
the primary antibody, incubation occurred for 1 hour on a nutator at room
temperature. When the membrane was incubated using PGRMC2 or PAIRBP1 as
the primary antibody, the membrane was incubated in solution overnight on a
nutator at 4˚C. The membrane was then washed in blocking buffer 3 separate
times, for 10 minutes each, on a shaker at room temperature.
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Table 4: Secondary HRP-conjugated antibodies used for western blotting
Secondary
antibody
goat antimouse
goat antirabbit
rabbit antigoat

rabbit antimouse

Company

Indirectly detects
expression of
PAIRBP1
Thermo
NL181270 indirectly detects
Scientific Pierce
expression of
Antibodies
PGRMC1
Thermo
OE1711053 indirectly detects
Scientific Pierce
expression of
Antibodies
PGRMC2

Dilution in
BB
1:10,000
(1 µL:10
mL)
1:10,000
(1 µL:10
mL)
1:10,000
(1 µL:10
mL)

Pierce Immuno
Pure
Antibodies

1:10,000
(1µL:10
mL)

Pierce Immuno
Pure Antibodies

Lot
Number
FI814529

Antibody function

BC631905

indirectly detects
expression of
GAPDH and
PAIRBP1

Next, the membrane was incubated in a solution of the secondary
Horseradish Peroxidase (HRP) antibody diluted in blocking buffer. As shown in
Table 4, the antibody dilution used for every secondary antibody was 1:10,000, so
1 µL of secondary antibody was diluted in 10 mL of blocking buffer. The origin
of the secondary antibody depended on the origin of the primary antibody being
used, because in order to bind to the primary antibody, it was essential that the
secondary antibody recognized the primary antibody as an antigen. The
incubation in the secondary antibody dilution took place on a nutator, at room
temperature, for 1 hour. Then, the membrane was washed in blocking buffer 2
additional times, for 10 minutes each, on a shaker at room temperature. The
membrane was then washed once in wash buffer, consisting of 50 µL of Tween
diluted in 1 L of 1x PBS, for 10 minutes on a shaker at room temperature. The
membrane was then quickly rinsed in 1x PBS and incubated in 5 mL of a
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detection buffer-enhancer solution for 5 minutes on a shaker at room temperature.
The ratio of detection buffer to enhancer was 1:1, so 2.5 mL of each liquid was
used in the solution. The membrane was then thoroughly rinsed in milli-Q water,
wrapped in a clear plastic cover and placed in an autoradiography cassette. The
membrane was then imaged using a BioRad Molecular Imaging ChemiDoc XRS+
Imaging System specialized for western blot detection. Protein bands of interest
and the intensity of protein expression were detected across different stages of
mouse development based on the size, shade and location of the bands. Images
were captured on a program connected to the imaging system and were stored for
future reference. Once imaging was complete, the membrane was rinsed in 1x
PBS and blocked in blocking buffer for 30 minutes on a shaker at room
temperature. Then, the blocking buffer was changed and the membrane was
incubated in blocking buffer overnight at 4˚C.
The following day, the detection protocol was repeated, except different
antibodies were substituted as the primary and secondary antibodies. The
membrane was reprobed using the loading control protein, glyceraldehyde-3phosphate dehydrogenase (GAPDH). GAPDH was used as the primary antibody;
diluted 1:5000 in blocking buffer. The secondary antibody used was an antimouse HRP antibody, since GAPDH is made in mouse, and was diluted 1:10,000
in blocking buffer. The reprobing procedure was used to ensure that equal
amounts of sample were loaded into each well to confirm that resulting
differences in signal strength were not simply due to over-loading or underloading of a well. GAPDH is an efficient loading control protein to use because it
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is stable across various conditions and typically possesses dependable signal
strength.

Results

PGRMC1 appears to be expressed in the surface epithelium of the fetal and
neonatal mouse ovary

The technique of immunocytochemistry was performed to determine if PGRMC1
was expressed in the fetal mouse ovary at 15.5 dpc and 17.5 dpc and in the
neonatal mouse ovary at PND 1, 3 and 5.
The expression of PGRMC1 appears to be limited to the epithelium of the
fetal and neonatal mouse ovaries, as shown in Figure 5A, C and E. The staining of
the epithelial cells with the PGRMC1 antibody is relatively strong and appears to
localize to the cytoplasm, as well as the nuclei of these cells. The rate at which the
antibody detection diffuses as you progress towards the ovary interior is
inconsistent and varies from one ovary to another. PGRMC1 was not detected in
the ovary interiors of these 3 stages, as shown in Figure 5B, D and F.
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A

B

15.5 dpc

C

15.5 dpc

D

PND 1

PND 1

F

E

PND 5

PND 5

Figure 5: Confocal images of fetal and neonatal mouse ovary sections
demonstrating expression of PGRMC1 via the PGRMC1 antibody staining
(green) at the epithelial layer of the ovary. The propidium iodide (red) is staining
the nuclei of the oocytes, surrounding pre-granulosa and epithelial cells. Images
of the epithelial cells at 15.5 dpc (A), PND 1 (C) and PND 5 (E) are shown in
comparison to images of the ovary interior at 15.5 dpc (B), PND 1 (D) and PND 5
(F).
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PGRMC2 does not appear to be expressed at all throughout fetal and
neonatal mouse ovary development

The technique of immunocytochemistry was performed to determine if
PGRMC2 was expressed in the fetal mouse ovary at 15.5 dpc and 17.5 dpc and
the neonatal mouse ovary at PND 1, 3 and 5.

A

B

15.5 dpc

C

PND 1

PND 5

Figure 6: Confocal images of fetal and neonatal mouse ovaries showing no
expression of PGRMC2 via the PGRMC2 antibody (green). The propidium iodide
(red) is staining the nuclei of the oocytes and the somatic, or granulosa, cells.
Ovaries at 15.5 dpc (A), PND 1 (B) and PND 5 (C) only show appropriate
staining of nuclei within various ovary components.

There does not appear to be any significant expression of PGRMC 2 in the
mouse ovary at these stages of fetal and neonatal mouse development, as shown
in Figure 6. There was no expression in the cytoplasm or nuclei of the oocytes or
the surrounding somatic cells at 15.5 dpc or PND 5. In several ovaries at PND 1,
the ovaries appear to have weak background staining with no specific localization
pattern; therefore expression of PGRMC2 in the neonatal mouse ovary is not
significant at PND 1 either.
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PAIRBP1 appears to be expressed in the epithelium of the fetal and neonatal
mouse ovary

The technique of immunocytochemistry was performed to determine if
PAIRBP1 was expressed in the fetal mouse ovary at 15.5 dpc and 17.5 dpc and
the neonatal mouse ovary at PND 1, 3 and 5.

A

B

C

15.5 dpc

PND 1

D

PND 1

E

PND 5

PND 5

Figure 7: Confocal images of fetal and neonatal mouse ovary sections
demonstrating expression of PAIRBP1 via the PAIRBP1 antibody staining
(green) at the epithelial layer of the neonatal ovary. The propidium iodide (red) is
staining the nuclei of the oocytes, surrounding pre-granulosa and epithelial cells.
An image of the ovary at 15.5 dpc (A) is shown. Images of the epithelial cells in
the neonatal ovary at PND 1 (B) and PND 5 (D) are shown in comparison to
images of the ovary interior at PND 1 (C) and PND 5 (E).
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The expression of PAIRBP1 appears to be limited to the epithelium of the
fetal and neonatal mouse ovaries, as shown in Figure 7. The staining of the
epithelial cells with the PAIRBP1 antibody is relatively strong and appears to
localize to the cytoplasm, as well as the nuclei of these cells. The rate at which the
antibody expression diffuses as you progress towards the ovary interior is
inconsistent and varies from one ovary to another. PAIRBP1 was not detected in
the ovary interiors of these 3 stages, as seen in Figure 7. This correlation between
PAIRBP1 expression and PGRMC1 expression could potentially support the
hypothesis that PGRMC1 and PAIRBP1 interact in order for the PGRMC1progesterone signaling pathway to proceed normally.

PGRMC1 appears to be present throughout fetal and neonatal mouse
development

The western blotting procedure was performed to confirm that PGRMC1
is present in the fetal and neonatal mouse ovary and to determine if the levels of
this membrane receptor change throughout the process of germ line development.
The expected size of PGRMC1 is 28 kilo Daltons (kD). Ovary extracts at 15.5
dpc, 17.5 dpc, PND 1, PND 3 and PND 5 were tested using western blot.
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Figure 8: Image taken from the BioRad Molecular Imaging ChemiDoc XRS+
Imaging System showing the PGRMC1 western blot results. The prominently
detected protein is PGRMC1. Lane 1 consists of the Precision Plus Standard
Protein marker used as a reference to determine band size. The arrow shows a 25
kD size marker. Lane 2 consists of the HepG2 whole cell lysate positive control.
Lane 3 consists of ovary extracts at 15.5 dpc. Lane 4 consists of ovary extracts at
17.5 dpc. Lane 5 consists of ovary extracts at PND 1. Lane 6 consists of ovary
extracts at PND 3. Lane 7 consists of ovary extracts at PND 5.

The western blot membrane detection demonstrates that PGRMC1 is
present in the fetal and neonatal mouse ovary from 15.5 dpc to PND 5, as seen in
Figure 8. The protein detected appears to be of the appropriate size expected for
PGRMC1. The protein appears to be slightly larger than the 25 kD reference
protein size marker, while still being significantly smaller than the 37 kD
reference protein. The HepG2 whole cell lysate that was used as a positive control
appeared to have protein detected at the same size as the PGRMC1 protein (28
kD), which is to be expected considering that the positive control lysate sample
contains PGRMC1. An additional protein in the HepG2 whole cell lysate was also
detected at approximately 20 kD. The darkness, or intensity, of the protein from
15.5 dpc to PND 5 appears to be consistent. This demonstrates that the level of
PGRMC1 in the mouse ovary across germ line development is relatively stable
and does not fluctuate significantly. An additional protein was detected at each of
the ages, located slightly above the 100 kD reference size marker. It is not
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included in Figure 8, because it is not the primary protein signifying the presence
of PGRMC1 in the fetal and neonatal mouse ovary.
The western blotting detection procedure was repeated using the loading
control protein, GAPDH. The same membrane was re-probed using this antibody
to determine if an equal amount of sample was loaded into each of the wells in
order to ensure that any change in the protein signal intensity was inherently due
to a change in expression of the PGRMC1 receptor at that stage of development.
The expected size of GAPDH is 42 kD, and the same ovary extract ages in Figure
8 were used here.
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4

5

6

7

37 kD

Figure 9: Image taken from the BioRad Molecular Imaging ChemiDoc XRS+
Imaging System showing the GAPDH reprobing results for PGRMC1. The
prominently detected protein is GAPDH. Lane 1 consists of the Precision Plus
Standard Protein marker used as a reference to determine protein size. The arrow
shows a 37 kD size marker. Lane 2 consists of the HepG2 whole cell lysate. Lane
3 consists of ovary extracts at 15.5 dpc. Lane 4 consists of ovary extracts at 17.5
dpc. Lane 5 consists of ovary extracts at PND 1. Lane 6 consists of ovary extracts
at PND 3. Lane 7 consists of ovary extracts at PND 5.

The results from the western blot membrane re-probing procedure, as
shown in Figure 9, demonstrating that the results from the PGRMC1 detection are
relatively accurate. The protein detected appears to be of the appropriate size for
GAPDH. The protein appears to be located slightly above the 37 kD reference
band, while still being a moderate distance from the 50 kD reference band, which
demonstrates that it was detected at the expected location on the membrane. An
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additional protein was detected at approximately 37 kD; the size was difficult to
determine given the non-linear shape that progressed across the lanes on the
membrane. The darkness, or intensity, of the bands appears to change slightly
across the 5 developmental ages. The band detected at 17.5 dpc appears to be
slightly lighter than the other bands detected, especially in comparison to the
bands detected at PND 1 and PND 3. The slight fluctuation in protein signal
intensity of GAPDH could demonstrate that some volumes of sample loaded were
slightly less than or slightly more than the instructed 20 µL. Given the slight
fluctuation in the intensity of the GAPDH protein signal, the PGRMC1 levels
shown in Figure 8 might require re-evaluation. Faint protein signals were also
detected at approximately 28 kD and 100 kD, but are not shown above. These
proteins are not shown in Figure 9, because they are remnants from the PGRMC1
detection.

PGRMC2 does not appear to be present throughout fetal and neonatal
mouse development

The western blotting procedure was performed to confirm that PGRMC2
is not present in the fetal and neonatal mouse ovary and to determine if the levels
of this membrane receptor change throughout the process of germ line
development. The expected size of PGRMC2 is 24 kD. Ovary extracts at 15.5
dpc, 17.5 dpc, PND 1, PND 3 and PND 5 were tested using western blot.
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Figure 10: Image taken from the BioRad Molecular Imaging ChemiDoc XRS+
Imaging System showing the PGRMC2 western blot results. There were no
prominently detected proteins for PGRMC2. Lane 1 consists of the Precision Plus
Standard Protein size marker. The arrow shows a 25 kD size marker. Lane 2
consists of the HeLa whole cell lysate. Lane 3 consists of ovary extracts at 15.5
dpc. Lane 4 consists of ovary extracts at 17.5 dpc. Lane 5 consists of ovary
extracts at PND 1. Lane 6 consists of ovary extracts at PND 3. Lane 7 consists of
ovary extracts at PND 5.

The western blot experiment did not detect PGRMC2 in the fetal and
neonatal mouse ovary extracts, as shown in Figure 10. If PGRMC2 were
expressed in the fetal and neonatal mouse ovary, a protein of approximately 24
kD would be expected to be detected in the blot. However, there were no proteins
detected at the appropriate location expected for PGRMC2. A protein of the
expected size for PGRMC2 was detected in the HeLa whole cell lysate that was
used as a positive control. This demonstrates that it was possible for PGRMC2 to
be detected in at least one sample on the blot. An additional protein was detected
at approximately 15 kD, as well as an un-identifiable spot slightly below the 100
kD reference band. Since no protein signals were detected upon imaging the
membrane, the darkness, or intensity, of PGRMC2 was unable to be determined.
The western blotting detection procedure was repeated using the loading
control protein, GAPDH. Typically, this procedure would be used to determine if
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an equal amount of sample was loaded into each of the wells in order to ensure
that any change in protein signal intensity was inherently due to a change in
expression of the PGRMC2 receptor at that stage of development. In this case, the
membrane was re-probed in order to determine if the original lack of PGRMC2
expression was due to an error in how the PGRMC2 western blot was conducted,
or if there was an error with the antibody itself. The expected size of GAPDH is
42 kD, and the same ovary extract ages in Figure 10 were used here.
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Figure 11: Image taken from the BioRad Molecular Imaging ChemiDoc XRS+
Imaging System showing the GAPDH reprobing results for PGRMC2. The
prominently detected protein is GAPDH. Lane 1 consists of the Precision Plus
Standard Protein size marker. The arrow shows a 37 kD size marker. Lane 2
consists of the HeLa whole cell lysate. Lane 3 consists of ovary extracts at 15.5
dpc. Lane 4 consists of ovary extracts at 17.5 dpc. Lane 5 consists of ovary
extracts at PND 1. Lane 6 consists of ovary extracts at PND 3. Lane 7 consists of
ovary extracts at PND 5.

The results from the western blot re-probing procedure demonstrated that
GAPDH was detected from 15.5 dpc to PND 5, as shown in Figure 11. As shown
by the 37 kD reference protein, the protein signal detected appears to be at the
appropriate size for GAPDH, only having a slightly different mobility than
expected. The consistent darkness of the detected protein signal demonstrates that
an equal amount of sample was loaded into each of the wells upon the original
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running of the gel; therefore the lack of PGRMC2 detection in Figure 10 was not
a result of a severely decreased amount of ovary extract present during gel
electrophoresis. The proteins in Lane 2 of Figure 11, representing the HeLa whole
cell lysate positive control, appear to be slightly smeared, which might indicate
that too much of the positive control was used. Definitive protein signals were
detected from 15.5 dpc to PND 5, demonstrating that the lack of PGRMC2
expression in Figure 10 is most likely not a result of an error in the western blot
procedure. These results help narrow down the possible reasons as to why
PGRMC2 was consistently not detected at all in the mouse ovary throughout fetal
and neonatal development across a number of western blot experiments.

PAIRBP1 expression appears to increase across fetal and neonatal mouse
development

The western blotting procedure was performed to confirm that PAIRBP1
is present in the fetal and neonatal mouse ovary and to determine if the levels of
this protein change throughout the process of germ line development. The
expected size of PAIRBP1 is 45 kD. Ovary extracts at 15.5 dpc, 17.5 dpc, PND 1,
PND 3 and PND 5 were tested using western blot.
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Figure 12: Image taken from the BioRad Molecular Imaging ChemiDoc XRS+
Imaging System showing the PAIRBP1 western blot results. The prominently
detected protein is PAIRBP1. Lane 1 consists of the Precision Plus Standard
Protein size marker. The arrow shows a 50 kD size marker. Lane 2 consists of the
HeLa whole cell lysate. Lane 3 consists of ovary extracts at 15.5 dpc. Lane 4
consists of ovary extracts at 17.5 dpc. Lane 5 consists of ovary extracts at PND 1.
Lane 6 consists of ovary extracts at PND 3. Lane 7 consists of ovary extracts at
PND 5.

The western blot membrane detection demonstrates that PAIRBP1 is
present in the fetal and neonatal mouse ovary at various levels across germ line
development, as shown in Figure 12. The protein detected appears to be located at
approximately the appropriate location correlating with the expected size of
PAIRBP1. The protein appears to be in line with the 50 kD reference band, which
is slightly above the expected 45 kD PAIRBP1 size. However, the expected size
for any given protein is simply an estimate that can fluctuate based on a number
of different occurrences during the western blot procedure. The PAIRBP1 protein
detected only slightly deviated from the estimate; therefore these results maintain
their validity. The HeLa whole cell lysate that was used a positive control did not
appear to express PAIRBP1 upon treatment with the PAIRBP1 antibody, which
was unexpected. The darkness, or intensity, of each protein signal from 15.5 dpc
to PND 5 appears to increase as development progresses. According to the protein
signal intensities, the expression of PAIRBP1 in the mouse ovary steadily
increases as germ line development proceeds.
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The western blotting detection procedure was repeated using the loading
control protein, GAPDH. The same membrane was re-probed using this antibody
to determine if an equal amount of sample was loaded into each of the wells in
order to ensure that any change in protein signal intensity was inherently due to a
change in expression of the PAIRBP1 receptor at that stage of development. The
expected size of GAPDH is 42 kD, and the same ovary extract ages in Figure 12
were used here.
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Figure 13: Image taken from the BioRad Molecular Imaging ChemiDoc XRS+
Imaging System showing the GAPDH reprobing results for PAIRBP1. The
prominently detected protein is GAPDH. Lane 1 consists of the Precision Plus
Standard Protein marker. The arrow shows a 37 kD size marker. Lane 2 consists
of the HeLa whole cell lysate. Lane 3 consists of ovary extracts at 15.5 dpc. Lane
4 consists of ovary extracts at 17.5 dpc. Lane 5 consists of ovary extracts at PND
1. Lane 6 consists of ovary extracts at PND 3. Lane 7 consists of ovary extracts at
PND 5.

The results from the western blot re-probing procedure demonstrated that
GAPDH was detected from 15.5 dpc to PND 5, as seen in Figure 13. As shown by
the 37 kD reference size marker, GAPDH is detected at the appropriate size,
showing only a slightly different mobility on the membrane than expected in
comparison to the protein size marker. Figure 13 also demonstrates that the results
from the PAIRBP1 detection were relatively accurate. It appears as though a
relatively consistent amount of sample was loaded into each of the wells based on
the similar protein signal intensities seen from 15.5 dpc to PND 5. The HeLa
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whole cell lysate in Lane 2 of Figure 13 appears to be completely bleached out
upon detection, which means that an excess amount of positive control lysate
could have been used, causing the GAPDH protein signal to be overexpressed to
such an extreme. The results of the PAIRBP1 re-probing demonstrate that the
PAIRBP1 expression pattern shown in Figure 12 is relevant and could be due to
the intrinsic variation in expression of the protein across fetal and neonatal mouse
development. The results in Figure 13 ensure that the expression of PAIRBP1 in
the neonatal mouse ovary at PND 3 and PND 5 is significantly greater than at
earlier fetal and neonatal ages.

Discussion

Although issues with infertility might not entail life-threatening scenarios,
there is still a great deal of relevance in conducting research in order to learn more
about the potential processes and mechanisms that could contribute to this
dysfunction. A major issue that correlates with infertility is the fact that once
women establish their finite supply of viable ovaries, approximately around their
time of birth, there is no action that can be taken to increase their supply or
reverse permanent damage beyond that crucial developmental stage. It is for this
reason that a great deal of research is currently being conducted in order to gain
an in-depth understanding of the complex processes and pathways that are utilized
throughout germ line development. If we can learn more about the intricate,
interdependent processes that are occurring during this critical timeframe, then
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perhaps we can gain a better understanding of how fertility dysfunctions occur
and how we could eradicate or compensate for those dysfunctions in the future.
Looking specifically at the role of hormone function throughout the
process of germ line development, estrogen and progesterone are two hormones
that are considered foundational contributors and are known to affect various
aspects of development. Changes in levels of these hormones across development
are known to be correlated with certain phases in the process of germ line
development, acting as essential triggers for time-sensitive processes. However,
excess amounts of these same hormones are known to have an equally negative
effect on certain phases in this process, which, in turn, have a significant lasting
effect on the overall developmental outcome.
Previous research has demonstrated that increased levels of estrogen and
progesterone in the fetal and neonatal mouse ovary have an inhibitory effect on
the process of cyst breakdown (Chen et al., 2007). By inhibiting the breakdown of
cysts into single primordial follicles, the overall percent of viable individual
oocytes is drastically decreased. Instead of containing a large percentage of viable
oocytes for future fertilization, the neonatal ovary is more likely to contain a more
prominent number of MOF’s, which are thought to be unviable for future
reproductive use. It is scenarios such as this that could contribute to increased
chances for future infertility issues in females that were exposed to amplified
levels of estrogen or progesterone at a critical time in reproductive development.
A great deal of research has been conducted revolving around the roles of
estrogen and the negative effects that excess treatment of the hormone can have
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on the process of germ line development. In comparison, the role of progesterone
and the effects that excess levels of the hormone can have on developmental
processes is less researched and less understood. We are less knowledgeable
about the specific signaling pathways, receptors and affiliated proteins involved in
progesterone signaling, which is why the research discussed here was conducted.
We hoped to focus on specific progesterone signaling pathway receptors and
proteins utilized across germ line development in mice in an attempt to gain
information about how the overall role of progesterone might be dynamic,
changing in function at different stages in reproductive development.
Our research yielded a number of different results through experiments in
immunocytochemistry and western blotting. Our results demonstrated that the
PGRMC1 receptor and the interacting PAIRBP1 protein are both present in some
capacity across germ line development in the fetal and neonatal mouse ovary,
ranging from 15.5 dpc to PND 5. However, the expression of both of these
progesterone signaling components were limited to the epithelial layer of the
ovary. As constituents that are both thought to be actively involved in the
progression and development of individual oocytes, we would have expected to
see PGRMC1 and PAIRBP1 expressed, in one capacity or another, within the
actual developing oocytes themselves. The spatial limitation of the receptor and
protein could present a localization pattern found within developing fetal and
neonatal mouse ovaries or the limitation could signify an error in the staining
ability of the given antibodies. The lack of penetration of the antibody signal
beyond the epithelial layer of the mouse ovary could be cognizant of a penetration
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error of the appropriate antibody or an error in the whole mount antibody staining
protocol that was utilized. Since the propidium iodide that was used to stain the
nuclei of the cells within the ovary was capable of penetrating the entire ovary, it
is most likely an issue with the anti-PGRMC1 and anti-PAIRBP1 antibodies that
were utilized for this research. These experiments need to be repeated again,
possibly altering the concentrations of the current primary antibodies or ordering
a completely new lot of each antibody in order to continue testing the expression
of PGRMC1 and PAIRBP1 in the mouse ovary across these crucial
developmental stages.
Unfortunately, the experiment conducted to test the expression of
PGRMC2 in the mouse ovary from 15.5 dpc to PND 5 yielded no conclusive
results. Unlike the epithelial expression characteristic of the experiments
conducted with PGRMC1 and PAIRBP1, PGRMC2 was not detected in the fetal
or neonatal mouse ovary. Previous studies in the Pepling Lab detected PGRMC2
at 15.5 dpc, using the same antibody and technique that was used here, so these
results were extremely unexpected and unexplainable. According to the results
obtained here, PGRMC2 is not expressed in the developing ovary and therefore
could not play a role in progesterone signaling pathways in the mouse ovary. If
PGRMC2 were not expressed in the developing mouse ovary, then all
progesterone signals entering the cell at the membrane level would have to be
utilizing the PGRMC1 signaling pathway, which seems questionable. However, if
certain progesterone signaling pathways, such as the PGRCM2 pathway, were not
active during hormone treatments in which the ovaries are exposed to excess
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amounts of progesterone, would that affect the amount of progesterone that is able
to signal cells to inhibit cyst breakdown?
In terms of the PGRMC2 immunocytochemistry experiment, it is more
likely that there was some error in the experimental method used. More
knowledge needs to be obtained to learn how the previous experiment that
successfully demonstrated the expression of PGRMC2 in the fetal and neonatal
mouse ovary was conducted. This experiment needs to be repeated after obtaining
that knowledge and certain aspects of the protocol will need to be altered. Perhaps
a change in the corresponding anti-PGRMC2 primary or secondary antibody
concentration needs to be altered in order for the antibody to penetrate the entire
mouse ovary.
Overall, the results of the immunocytochemistry experiments did not
provide any conclusive data. More experiments similar in nature to the
experiments conducted in this research study will need to be altered and repeated
in the hopes that more conclusive results can be obtained. The only result that
could potentially support a current theory is the overlapping localization of both
PGRMC1 and PAIRBP1 in the fetal and neonatal mouse ovary. The interaction
between this membrane receptor and protein is not well understood, but thought
to be necessary in order for the PGRMC1-progesterone signaling pathway to
function properly, so it is logical to assume that these two progesterone signaling
pathway components are co-localizing to the same region of the mouse ovary.
The results obtained from western blotting experiments yielded variable
data, as well. Our results demonstrated that PGRMC1 is expressed at relatively
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constant levels in the mouse ovary across germ line development. According to
the role that PGRMC1 plays in the progesterone signaling pathway, we would not
expect the membrane receptor to be present at consistent levels from 15.5 dpc to
PND 5. Given progesterone’s inhibitory function in cyst breakdown, perhaps we
would expect progesterone, and therefore PGRMC1, to be expressed at decreased
levels during the timeframe in germ line development when cyst breakdown is
thought to occur, from approximately 17.5 dpc to PND 5. However, according to
the western blot results, PGRMC1 is still strongly expressed in ovaries at these
crucial ages. These results could raise further questions about the role of
PGRMC1 in the progesterone signaling pathway in the ovary across fetal and
neonatal mouse development. Perhaps more research needs to be conducted in
order to determine the limitations and functions of this membrane receptor, which
might fulfill additional functions that we are not yet aware of. The constant
expression of PGRMC1 in the mouse ovary from 15.5 dpc to PND 5 could also be
a result of several possible errors in the western blot protocol and technique. For
example, perhaps more ovary extract sample was loaded into the wells at several
of the ages, such as PND 1 and PND 3, which could affect the intensity of the
bands upon detection and, in turn, alter the interpretation of the results. This is
why re-probing with GAPDH is often performed in order to account for
discrepancies such as this. Re-probing with the GAPDH loading control informed
us that further tests need to be conducted using PGRMC1 in order to validate the
expression of this receptor across germ line development.
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Results from the western blot testing for the presence and intensity of
PGRMC2 across germ line development were also unexpected. Even though a
variety of antibody dilutions were used and several different incubation methods
were tested, we did not find any expression of PGRMC2 in the fetal and neonatal
mouse ovary from 15.5 dpc to PND 5. No bands of interest were detected at any
of the developmental ages tested. Several different PGRMC2 antibodies were
tested and a number of alterations were made to the western blot protocol in an
attempt to detect PGRMC2, but PGRMC2 did not appear to be expressed across
any of the experimental trials. These results also align with the results obtained
from the immunocytochemistry experiments, which showed no detection of
PGRMC2 via antibody staining. The complete lack of PGRMC2 detection in both
experiments strengthens the argument that PGRMC2 is not functioning in the
process of germ line development in the capacity that we had anticipated. Perhaps
PGRMC2 is not playing a role in germ line development directly within the fetal
and neonatal mouse ovary, but the membrane receptor is instead playing an
indirect role. This could explain why PGRMC2 is not directly expressed in the
mouse ovary across this critical developmental time period.
There could be several errors in the western blot protocol and technique
used, though, which could explain the unexpected results for PGRMC2
expression in the fetal and neonatal mouse ovary. Two different PGRMC2
antibodies, obtained from two different biotechnology companies, were tested,
which leads us to believe that the lack of detectable protein signal is not a result of
dysfunctional antibodies However, there could have been errors in the method
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that was used to block insignificant bands from detection on the transfer
membrane. One of the primary PGRMC2 antibodies that was used for a number
of western blot experiments was made in goat. Since this antibody was made in
goat and goats are closely related to cows, the chances of a cross-reaction between
a blocking buffer containing milk and a secondary anti-goat antibody are thought
to be increased. In order to ensure that any insignificant bands would be properly
blocked, it was recommended that we substitute the 5% non-fat dry milk with
goat serum. However, this alteration in the protocol led to several errors in the
procedure. An appropriate amount of goat serum was not substituted into the
blocking buffer solution, with only 50 µL of goat serum being added to each liter
of blocking buffer instead of the 5 mL of goat serum that would be necessary in
order to equal 5% of the overall blocking buffer solution volume. Adding such a
small amount of goat serum in comparison to the remainder of the solution
components could easily affect the results of each western blot that the blocking
buffer was used in. Also, we recently learned about a contradicting theory
recommending that when using primary antibodies made in goat for a western
blot, a serum corresponding to the secondary anti-goat antibody should be used
instead. For example, instead of substituting the 5% non-fat dry milk with goat
serum each time blocking buffer solution was made, we should have used rabbit
serum as a substitute instead, seeing as the secondary anti-goat antibody was
made in rabbit. Upon first considering these discrepancies, we thought that
perhaps altering these steps in the western blot protocol would yield different, or
even more conclusive, results. However, the discrepancies discussed above would
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be thought to cause insufficient blocking of insignificant proteins, but the major
issue in this research was the complete lack of detectable PGRMC2 signal. For
this reason, more thought needs to be given to these technical discrepancies and
further experimental tests need to be conducted in order to determine their effects.
The results obtained from the western blots investigating PAIRBP1
expression in the mouse ovary across germ line development were quite
interesting. Given the significant interaction that is thought to be present between
PGRMC1 and PAIRBP1 in the PGRMC1-progesterone signaling pathway, we
would have expected to see a similar detection pattern for PAIRBP1 bands of
interest from 15.5 dpc to PND 5. However, PAIRBP1 appeared to be only faintly
detected at 15.5 dpc, and then continually gained band intensity as germ line
development proceeded. The western blot results suggested that the protein
exhibits a definitive expression trend, where PAIRBP1 expression directly
increases as the age of the mouse ovaries increase.
Perhaps this difference in detection between PGRMC1 and PAIRBP1
could have something to do with the anti-apoptotic function that PAIRBP1 is
thought to be involved in in the PGRMC1-progesterone signaling pathway.
Levels of PAIRBP1 expression could be lower in the days of fetal development
leading up to the commencement of germ cell death, or apoptosis, which is
thought to begin at approximately 18 dpc. Lower levels of this protein could act
as some sort of trigger that initiates the apoptotic process. After the initiation of
germ cell death, PAIRBP1 expression could strengthen. This could happen in
order to ensure that the PGRMC1-progesterone signaling pathways anti-apoptotic
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function is serving to terminate the apoptotic phase of germ line development,
which ends at approximately PND 4.5. In order for this PAIRBP1 expression
pattern to be valid, it would require some type of delay between the time at which
PAIRBP1 levels change and the subsequent germ line development phase is
initiated. A wider range of fetal and neonatal mouse ages would need to be tested
in order to further explore this idea.
There are several technical errors that could account for the interesting
PAIRBP1 detection results that were obtained. Unfortunately, not a great deal of
time was able to be dedicated to investigating this particular protein so, in order to
validate the results shown in Figure 12, a number of western blot experiments
would need to be repeated using the same antibody dilution and incubation
procedures. Also, the differences in the band intensities across each of the 5 ages
tested could be a result of unequal loading of samples into each well upon the
initial running of the gel. If a smaller amount of sample from 15.5 dpc or 17.5 dpc
was loaded than sample from several of the postnatal ages, then that could explain
the weaker band detection at those fetal ages.
Overall, the results obtained from the western blot experiments yielded a
number of different unexpected, but intriguing results. The complete lack of
detection of PGRMC2 expression in the fetal and neonatal mouse ovary across
germ line development aligns with the results obtained in the
immunocytochemistry experiment, but will obviously require further research
since the complete non-existence of PGRMC2 in the mouse ovary at any point in
germ line development is not likely. The protein blot detection results for

56

PGRMC1 and PAIRBP1 do not correlate in the same manner as was seen in the
immunocytochemistry results for this membrane receptor and protein. Perhaps
PGRMC1 is required for a number of other functions that occur throughout the
process of germ-line development, whereas PAIRBP1 is limited to playing a role
in the PGRMC1-progesterone signaling pathway’s anti-apoptotic function. Even
so, the PAIRBP1 expression pattern that was detected by changes in band
intensity from 15.5 dpc to PND 5 does not precisely align with the germ cell death
timeframe that is shown in Figure 1, so a great deal more research will need to be
conducted in order to learn more about this protein individually, as well as its
interaction with PGRMC1.

Future Work

Given the variability of the results, as well as the unsuccessful completion
of several of the experiments, there is a great deal of future work that can be
conducted on this topic and the individual components of this research. Each of
the experiments conducted in this research study could be repeated, or altered and
repeated, to gain more conclusive and valid results. The overall age range used for
the immunocytochemistry and western blot experiments could be expanded to
include fetal ovaries at 13.5 dpc, as well as post natal ovaries at PND 7. Even
though the crucial timeframe during which cyst breakdown and apoptosis is
accounted for throughout this research study, it could always be beneficial to
obtain more results and gain more information across a wider age range
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Since some of the experimental methods used, such as the western blot,
required a variety of alterations in antibody dilutions, perhaps a different
experimental technique called a dot blot could be used. Dot blots could be used as
a simplification of the western blot technique, where ranges of different primary
antibody dilutions are tested on the sample of interest. This could be beneficial to
determine which antibody dilution will yield the best detectable band before
running an entire western blot with a number of different samples. Completing
dot blots prior to future western blots could help ensure that the antibody of
interest is functioning properly and at an optimal level before proceeding on to
future experimental tests.
The incorporation of organ culture experiments into further research on
this topic could be extremely beneficial in terms of investigating how changes in
the functioning of PGRMC1, PGRMC2 and/or PAIRBP1 have a lasting effect on
the progression of germ line development in the mouse ovary. Having the ability
to manipulate these signaling pathways via function-blocking antibodies would
allow us to analyze the direct effects that are had on the formation of primordial
follicles. Organ cultures could be conducted using ovaries at 13.5 dpc, 15.5 dpc
and PND 1, which would each be grown in culture for 5 days. Upon completion
of each function-blocking organ culture the ovaries, now 17.5 dpc, PND 1 and
PND 5, could be analyzed via immunocytochemistry using the same whole mount
antibody staining procedure that was used in this research study. Once the treated
ovaries were stained it would be possible to count and calculate the number of
individual oocytes in each ovary as a determinant of overall follicle development.
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The ability to calculate the approximate overall success of cyst breakdown and, in
turn follicle development, via oocyte counting would be extremely valuable in
quantifying the importance of progesterone signaling pathway components, such
as PGRMC1, PGRMC2 and PAIRBP1. Incorporating these types of experiments
into future research would bring an entirely new and significant dimension to this
topic of study.

59

References

Albrecht, C., Huck, V., Wehling, M., Wendler, A., 2012. In vitro inhibition of
SKOV-3 cell migration as a distinctive feature of progesterone receptor
membrane component type 2 versus type 1. Steroids. 77, 1543–1550.
Cahill, M. A., 2007. Progesterone receptor membrane component 1: an integrative
review. The Journal of Steroid Biochemistry and Molecular Biology. 105,
16-36.
Chandra, A., Martinez, G. M., Mosher, W. D., Abma, J.C., Jones, J., 2005.
Fertility, family planning, and reproductive health of U.S. women: data
from the 2002 National Survey of Family Growth. Vital Health Statistics.
25, 1-174.
Chen, Y., Jefferson, W.N., Newbold, R.R., Padilla-Banks, E., Pepling, M.E.,
2007. Estradiol, progesterone, and genistein inhibit oocyte nest breakdown
and primordial follicle assembly in the neonatal mouse ovary in vitro and
in vivo. Endocrinology. 148, 3580-90.
Chen, C., Sargent, C., Quilter, C., Yang, Z., Ren, J., Affara, N., Brenig, B.,
Lusheng, H., 2010. Cloning, mapping and molecular characterization of
porcine progesterone receptor membrane component 2 (PGRMC2) gene.
Genetics and Molecular Biology. 33, 471-474.
Dzadyk, M.N., unpublished
Dzadyk, M. N., Pepling, M. E., unpublished
Jefferson, W., Newbold, R., Padilla-Banks, E., Pepling, M.E., 2006. Neonatal
genistein treatment alters ovarian differentiation in the mouse: inhibition
of oocyte nest breakdown and increased oocyte survival. Biol Reprod. 74,
161-8.
Leonhardt, S., Boonyaratanakornkita, V., Edwards, D.P., 2003. Progesterone
receptor transcription and non-transcription signaling mechanisms.
Steroids. 68, 761-770.
Lösel, R. M., Besong, D., Peluso, J. J., Wehling, M., 2008. Progesterone receptor
membrane component 1―many tasks for a versatile protein. Steroids. 73,
929-934.
Peluso, J. J., 2006. Multiplicity of progesterone’s actions and receptors in the
mammalian ovary. Biol Reprod. 75, 2-8.

60

Peluso, J.J., Romak, J., Liu, X., 2008. Progesterone receptor membrane
component-1 (PGRMC1) is the mediator of progesterone’s antiapoptotic
action in spontaneously immortalized granulosa cells as revealed by
PGRMC1 small interfering ribonucleic acid treatment and functional
analysis of PGRMC1 mutations. Endocrinology. 149, 534-543.
Peluso, J. J., 2013. Progesterone receptor membrane component 1 and its role in
ovarian follicle growth. Frontiers in neuroscience, 7.
Pepling, M. E., 2006. From primordial germ cell to primordial follicle:
mammalian female germ cell development. Genesis. 44, 622-632.
Pepling, M.E., de Cuevas, M., Spradling, A.C, 1999. Germline cysts: a conserved
phase of germ cell development? Trends. Cell Biol. 9, 257–262.
Pepling, M.E., Spradling, A.C., 1998. Female mouse germ cells form
synchronously dividing cysts. Development. 125, 3323-3328.
Pepling, M.E., Spradling, A.C., 2001. The mouse ovary contains germ cell cysts
that undergo programmed breakdown to form follicles. Developmental
Biology. 234, 339-351.
Pepling, M.E., 2012. Follicular assembly: mechanisms of action. Reproduction.
143, 139-149.
Skinner, M. K., 2005. Regulation of primordial follicle assembly and
development. Human Reproduction Update. 11, 461–471.
Wendler A., Wehling M., 2013. PGRMC2, a yet uncharacterized protein with
potential as tumor suppressor, migration inhibitor, and regulator of
cytochrome P450 enzyme activity. Steroids. 78, 555–558.

61

Appendices

Figures
Figure 1. Timeline of Mouse Germ Cell Development, pg.10
Figure 2. Confocal images of a normal primordial follicle vs. a MOF,
pg.12
Figure 3. Estrogen, estradiol and progesterone, pg.12
Figure 4. Diagram of nuclear and membrane progesterone signaling
pathways, pg.14
Figure 5. Expression of PGRMC1, pg.35
Figure 6. Expression of PGRMC2, pg.36
Figure 7. Expression of PAIRBP1, pg.37
Figure 8. Detection of PGRMC1, pg.39
Figure 9. Detection of PGRMC1 GAPDH, pg.40
Figure 10. Detection of PGRMC2, pg.42
Figure 11. Detection of PGRMC2 GAPDH, pg.43
Figure 12. Detection of PAIRBP1, pg.45
Figure 13. Detection of PAIRBP1 GAPDH, pg.46
Tables
Table 1. Primary antibodies used in whole mount antibody staining
procedure, pg.23
Table 2. Secondary antibodies used in whole mount antibody staining
procedure, pg.24
Table 3. Primary antibodies/lysates used for western blot procedure, pg.31
Table 4. Secondary antibodies used for western blot procedure, pg.32
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